154 related articles for article (PubMed ID: 31033488)
21. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Kast RE; Ramiro S; Lladó S; Toro S; Coveñas R; Muñoz M
J Neurooncol; 2016 Feb; 126(3):425-31. PubMed ID: 26603162
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
23. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.
Bhattarai D; Singh S; Jang Y; Hyeon Han S; Lee K; Choi Y
Curr Top Med Chem; 2016; 16(19):2156-68. PubMed ID: 26881715
[TBL] [Abstract][Full Text] [Related]
24. Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.
Adasme MF; Bolz SN; Adelmann L; Salentin S; Haupt VJ; Moreno-Rodríguez A; Nogueda-Torres B; Castillo-Campos V; Yepez-Mulia L; De Fuentes-Vicente JA; Rivera G; Schroeder M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233837
[TBL] [Abstract][Full Text] [Related]
25. Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets.
Mudduluru G; Walther W; Kobelt D; Dahlmann M; Treese C; Assaraf YG; Stein U
Drug Resist Updat; 2016 May; 26():10-27. PubMed ID: 27180307
[TBL] [Abstract][Full Text] [Related]
26. Ropinirole, a potential drug for systematic repositioning based on side effect profile for management and treatment of breast cancer.
Rymbai E; Sugumar D; Saravanan J; Divakar S
Med Hypotheses; 2020 Nov; 144():110156. PubMed ID: 32763725
[TBL] [Abstract][Full Text] [Related]
27. Repurposing old drugs to fight multidrug resistant cancers.
Dinić J; Efferth T; García-Sosa AT; Grahovac J; Padrón JM; Pajeva I; Rizzolio F; Saponara S; Spengler G; Tsakovska I
Drug Resist Updat; 2020 Sep; 52():100713. PubMed ID: 32615525
[TBL] [Abstract][Full Text] [Related]
28. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL; Hoes LR; van der Wijngaart H; van Berge Henegouwen JM; van Werkhoven E; Roepman P; Schilsky RL; de Leng WWJ; Huitema ADR; Nuijen B; Nederlof PM; van Herpen CML; de Groot DJA; Devriese LA; Hoeben A; de Jonge MJA; Chalabi M; Smit EF; de Langen AJ; Mehra N; Labots M; Kapiteijn E; Sleijfer S; Cuppen E; Verheul HMW; Gelderblom H; Voest EE
Nature; 2019 Oct; 574(7776):127-131. PubMed ID: 31570881
[TBL] [Abstract][Full Text] [Related]
29. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
Cheng F; Hong H; Yang S; Wei Y
Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
[TBL] [Abstract][Full Text] [Related]
30. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.
Rundle-Thiele D; Head R; Cosgrove L; Martin JH
Br J Clin Pharmacol; 2016 Feb; 81(2):199-209. PubMed ID: 26374633
[TBL] [Abstract][Full Text] [Related]
31. In silico drug repositioning: what we need to know.
Liu Z; Fang H; Reagan K; Xu X; Mendrick DL; Slikker W; Tong W
Drug Discov Today; 2013 Feb; 18(3-4):110-5. PubMed ID: 22935104
[TBL] [Abstract][Full Text] [Related]
32. Repurposing Drugs in Oncology: Next Steps.
Verbaanderd C; Meheus L; Huys I; Pantziarka P
Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
[TBL] [Abstract][Full Text] [Related]
33. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.
Würth R; Thellung S; Bajetto A; Mazzanti M; Florio T; Barbieri F
Drug Discov Today; 2016 Jan; 21(1):190-199. PubMed ID: 26456577
[TBL] [Abstract][Full Text] [Related]
34. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
35. Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Katare PB; Banerjee SK
Curr Top Med Chem; 2016; 16(19):2189-200. PubMed ID: 26881721
[TBL] [Abstract][Full Text] [Related]
36. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
37. Computational drug repositioning for cancer therapeutics.
Jiao M; Liu G; Xue Y; Ding C
Curr Top Med Chem; 2015; 15(8):767-75. PubMed ID: 25732789
[TBL] [Abstract][Full Text] [Related]
38. Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead.
Shah RR; Stonier PD
J Clin Pharm Ther; 2019 Feb; 44(1):6-22. PubMed ID: 30218625
[TBL] [Abstract][Full Text] [Related]
39. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
Kim W; Lee Y; Jeong S; Nam J; Lee S; Jung Y
Arch Pharm Res; 2015 Oct; 38(10):1830-8. PubMed ID: 25860026
[TBL] [Abstract][Full Text] [Related]
40. Novel insight into drug repositioning: Methylthiouracil as a case in point.
Baek MC; Jung B; Kang H; Lee HS; Bae JS
Pharmacol Res; 2015 Sep; 99():185-93. PubMed ID: 26117428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
